Magic Mushrooms Show Promise for Cocaine Addiction

Scientists just discovered a potential breakthrough for cocaine addiction, a disorder that has no FDA-approved treatments despite killing thousands of Americans each year.

In a new clinical trial, 19 people who received a single dose of psilocybin (the active compound in magic mushrooms) were more likely to stay off cocaine than 17 people who got a placebo pill. Everyone in the study also worked with a therapist to process their experience.

Dr. Peter Hendricks, who led the study at the University of Alabama at Birmingham, says the timing couldn't be more urgent. Cocaine production has reached an all-time high globally, and overdose deaths involving stimulants keep climbing year after year.

What makes psilocybin different from other addiction medications is how it works. Most treatments target the same brain chemicals as the addictive substance itself, like nicotine patches or opioid replacement therapy. Psilocybin takes a completely different approach.

"It's more like a catalyst within a therapeutic process," explains Gabrielle Agin-Liebes, a clinical psychologist at Yale School of Medicine. The drug produces a profound shift in consciousness during a single therapy session, helping people see their behavior from new angles and develop more self-compassion.

Neuroscience researcher Robin Carhart-Harris believes psilocybin works by increasing the brain's ability to change both physically and psychologically. Addiction keeps people stuck in rigid patterns, and psychedelics might help break those cycles.

This approach could be especially effective for cocaine because withdrawal symptoms are more psychological than physical. People experience depression, agitation, and cravings rather than the intense physical pain of opioid or alcohol withdrawal.

Why This Inspires

This study represents another kind of breakthrough too. It's the first psychedelic clinical trial to include mostly Black participants, who made up the majority of the 36 people involved.

That matters because Black communities face disproportionate consequences from cocaine use disorder, even though white people report using cocaine more often. Black people are far more likely to be arrested for cocaine-related crimes, making effective treatment a matter of justice as well as health.

Most psychedelic research attracts wealthy, white participants through university networks and social media. Hendricks recruited differently, simply advertising for people trying to quit cocaine in Birmingham, Alabama. The result was a study population that actually reflects who needs help most.

The success of this small trial means psilocybin treatment for cocaine addiction is ready for larger studies that could eventually make it available to everyone struggling with stimulant addiction.